The U.S. Food and Drug Administration announced on October 1, 2026, that it approved the Autus Size-Adjustable Valve for pediatric patients with congenital pulmonary valve disease. The size-adjustable heart valve is surgically implanted and designed to be expanded later as a child grows. The FDA said it may reduce the need for repeat open-heart surgeries, although experience with expansion remains limited.
In its official approval announcement, the agency described two firsts: the first heart valve designed for expansion after surgery to accommodate childhood growth, and the first U.S.-approved heart valve using polymeric material rather than animal-derived tissue for its inner flaps, called leaflets.
Who may be affected by the approval?
The approval concerns children with congenital pulmonary valve disease who need pulmonary valve replacement. It is not an approval for every type of childhood heart defect or every heart valve position.
The FDA reported that congenital heart defects affect about 1 in every 100 U.S. births. Pulmonary valve stenosis, in which the valve is narrowed, and pulmonary valve atresia, in which it does not form normally, restrict blood flow from the heart to the lungs. Citing the Centers for Disease Control and Prevention, the announcement said these two conditions together affect around 4,200 babies in the United States annually.
Treatment can improve blood flow and help repair these defects, but some children are left with substantial pulmonary regurgitation, meaning blood leaks backward through the valve. Over time, that leakage can weaken or enlarge the right ventricle and create a need for valve replacement as the child grows.
How the size-adjustable heart valve works
The Autus valve can initially be implanted at approximately 13 millimeters in diameter, a size the FDA described as suitable for a toddler or preschool-aged child. It can later be widened using a balloon catheter—a small inflatable tube—to reach up to 22 millimeters, comparable to an adult-sized pulmonary valve.
The device does not simply grow on its own. Its design allows expansion after implantation as the child grows, potentially reducing the need to replace an outgrown valve through another open-heart operation.
Its polymeric leaflets open and close to control blood flow. According to the FDA, animal-derived tissue used in traditional valves tends to harden and break down faster in children, sometimes requiring earlier repeat surgery. One-year follow-up data suggest the Autus valve’s synthetic leaflets hold up well, but longer-term evaluation is continuing.
What the clinical study found
The approval was based on a study enrolling 62 pediatric patients at 12 U.S. sites. At six months, the first 60 patients showed acceptable blood-flow performance through the right side of the heart, with no more than mild backward leakage through the valve.
The FDA reported successful procedures for all study participants, with no deaths, blood clots requiring additional treatment, strokes or other clot-related complications. However, three patients experienced valve-frame fractures, and two had reduced movement of one leaflet. None of those events caused symptoms.
Valve performance began deteriorating in two patients who started to outgrow the device. Both had successful valve expansion without an invasive surgical procedure. The agency emphasized that experience remains limited. Longer-term studies are examining risks and whether expansion can maintain valve function and lead to fewer surgical procedures.
What readers should check in the official notice
The announcement does not provide home-care instructions, symptom-based safety steps or a treatment plan for families. Readers seeking the FDA’s stated patient population, study results, reported device problems or limitations should consult the linked official notice.
The device received approval through the FDA’s premarket approval pathway, its most stringent medical-device marketing application process. Edwards Lifesciences received the approval for the valve, which was developed by Autus Valve Technologies Inc.
Frequently Asked Questions
Does the valve grow automatically with a child?
No. It is designed to be widened after implantation using a balloon catheter as the child grows.
Does approval mean repeat surgery will never be needed?
No. The FDA said the device may reduce repeat open-heart surgeries. Longer-term studies are still evaluating valve function, risks and expansion outcomes.
Which children does this approval cover?
The FDA approved the surgically implanted pulmonary valve for pediatric patients with congenital pulmonary valve disease. The official notice provides the agency’s description of the intended population.
